420 related articles for article (PubMed ID: 32120227)
1. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
Corrao G; Marvaso G; Ferrara R; Lo Russo G; Gugliandolo SG; Piperno G; Spaggiari L; De Marinis F; Orecchia R; Garassino MC; Jereczek-Fossa BA
Lung Cancer; 2020 Apr; 142():70-79. PubMed ID: 32120227
[TBL] [Abstract][Full Text] [Related]
2. Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
Theelen WS; de Jong MC; Baas P
Lung Cancer; 2020 Apr; 142():106-113. PubMed ID: 32126451
[TBL] [Abstract][Full Text] [Related]
3. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.
Fitzgerald K; Simone CB
Thorac Surg Clin; 2020 May; 30(2):221-239. PubMed ID: 32327181
[TBL] [Abstract][Full Text] [Related]
4. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
5. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
[TBL] [Abstract][Full Text] [Related]
6. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
8. Management of Brain Metastases in Non-Small-Cell Lung Cancer.
Ernani V; Stinchcombe TE
J Oncol Pract; 2019 Nov; 15(11):563-570. PubMed ID: 31715122
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
10. Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases.
Abdulhaleem M; Johnston H; D'Agostino R; Lanier C; LeCompte M; Cramer CK; Ruiz J; Lycan T; Lo HW; Watabe K; O'Neill S; Whitlow C; White JJ; Tatter SB; Laxton AW; Su J; Chan MD
J Neurooncol; 2022 Mar; 157(1):101-107. PubMed ID: 35166988
[TBL] [Abstract][Full Text] [Related]
11. Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer.
Zhu L; Yu X; Tang X; Hu C; Wu L; Liu Y; Zhou Q
Chin Med J (Engl); 2024 May; 137(9):1019-1032. PubMed ID: 38251678
[TBL] [Abstract][Full Text] [Related]
12. The Combined Use of SBRT and Immunotherapy-a Literature Review.
Lubas MJ; Kumar SS
Curr Oncol Rep; 2020 Sep; 22(12):117. PubMed ID: 32929678
[TBL] [Abstract][Full Text] [Related]
13. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
14. Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy.
D'Andrea MA; Reddy GK
Am J Clin Oncol; 2020 Mar; 43(3):218-228. PubMed ID: 31842114
[TBL] [Abstract][Full Text] [Related]
15. Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer.
Churilla TM; Weiss SE
Curr Oncol Rep; 2018 May; 20(7):54. PubMed ID: 29736685
[TBL] [Abstract][Full Text] [Related]
16. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality.
Ko EC; Formenti SC
Int J Radiat Biol; 2019 Jul; 95(7):936-939. PubMed ID: 31120369
[No Abstract] [Full Text] [Related]
19. Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer.
Pizarro G; Pinto MP; Muñoz-Medel M; Cordova-Delgado M; Bravo ML; Nervi B; Sánchez C; Ibañez C; Peña J; Walbaum B; Madrid J; Briones J; Koch E; Valbuena J; Gonzalez S; Gejman R; Acevedo F; Mondaca S; Garrido M; Vines E; Galindo H
Clin Lung Cancer; 2020 Jul; 21(4):e250-e254. PubMed ID: 32088114
[No Abstract] [Full Text] [Related]
20. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
